Endocrinology and Metabolism

Yul Hwangbo (Hwangbo Y)

8 Articles

Thyroid
Seaweed and Iodine Intakes and SLC5A5 rs77277498 in Relation to Thyroid Cancer: Tung Hoang, Eun Kyung Lee, Jeonghee Lee, Yul Hwangbo, Jeongseon Kim; Endocrinol Metab. 2022;37(3):513-523. Published online May 24, 2022; DOI: https://doi.org/10.3803/EnM.2021.1306

1,669 View
91 Download
1 Citations

Abstract PDF Supplementary Material PubReader ePub Crossref - TDM

Background
This study aims to elucidate the associations among dietary seaweed (gim and miyeok/dashima) and iodine intakes, the rs77277498 polymorphism of the SLC5A5 gene codifying the sodium/iodine symporter, and thyroid cancer risk in a Korean population.
Methods
We conducted a case-control study of 117 thyroid cancer cases and 173 controls who participated in the Cancer Screenee Cohort between 2002 and 2014 at the National Cancer Center, Korea. The amount of seaweed and iodine consumption (g/day) was estimated using the residual energy adjustment method. We calculated odds ratios (ORs) and their 95% confidence intervals (CIs) using a multivariable logistic regression model for the separate and combined effect of dietary iodine-based intake and SLC5A5 polymorphism (rs77277498, C>G) on thyroid cancer.
Results
Dietary gim and iodine intakes were inversely associated with thyroid cancer, with ORs of 0.50 (95% CI, 0.30 to 0.83) and 0.57 (95% CI, 0.35 to 0.95), respectively, whereas the associations for dietary miyeok/dashima and total seaweed intakes were not significant. However, compared with individuals carrying the C/C genotype of the rs77277498 polymorphism with a low intake of all dietary factors, those carrying the G allele with a high intake had a lower risk of thyroid cancer, with ORs of 0.25 (95% CI, 0.10 to 0.56), 0.31 (95% CI, 0.12 to 0.77), 0.26 (95% CI, 0.10 to 0.62), and 0.30 (95% CI, 0.12 to 0.73) for the consumption of gim, miyeok/dashima, total seaweed, and iodine, respectively.
Conclusion
In summary, our results supported the evidence of the protective effects of dietary gim and iodine intake against thyroid cancer risk, and this association can be strengthened by SLC5A5 rs77277498 genotypes.

Citations

Citations to this article as recorded by

Iodine nutrition and papillary thyroid cancer
Xueqi Zhang, Fan Zhang, Qiuxian Li, Chuyao Feng, Weiping Teng
Frontiers in Nutrition.2022;[Epub] CrossRef

Clinical Study
A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol: Eun Kyung Lee, You Jin Lee, Young Joo Park, Jae Hoon Moon, Ka Hee Yi, Koon Soon Kim, Joo Hee Lee, Sun Wook Cho, Jungnam Joo, Yul Hwangbo, Sujeong Go, Do Joon Park; Endocrinol Metab. 2020;35(3):571-577. Published online September 22, 2020; DOI: https://doi.org/10.3803/EnM.2020.681

3,676 View
94 Download

Abstract PDF Supplementary Material PubReader ePub Crossref - TDM: Background
Radioactive iodine (RAI) remnant ablation is recommended in patients with papillary thyroid cancer (PTC) and extrathyroidal extension or central lymph node metastasis. However, there exists little evidence about the necessity of remnant ablation in PTC patients with low- to intermediate-risk, those have been increasing in recent decades.
Methods
This multicenter, prospective, non-randomized, parallel group clinical trial will enroll 310 eligible patients with low- to intermediate-risk of thyroid cancer. Inclusion criteria are patients who recently underwent total thyroidectomy for PTC with 3 or less tumors of size 1≤ to ≤2 cm with no microscopic extension and N0/x, or size ≤2 cm with microscopic extension and/or N1a (number of lymph node ≤3, size of tumor foci ≤0.2 cm, and lymph node ratio <0.4). Patients choose to undergo RAI ablation (¹³¹I, dose 1.1 GBq) or diagnostic whole-body scan (DxWBS) (¹³¹I or ¹²³I, dose 0.074 to 0.222 GBq), followed by subsequent measurement of stimulated thyroglobulin (sTg) within 1 year. Survey for quality of life (QOL) will be performed at baseline and at 1 year after follow-up. The total enrollment period is 5 years, and patients will be followed up for 1 year. The primary endpoint is the non-inferiority of surgery alone to surgery with ablation in terms of biochemical remission (BCR) rate (sTg ≤2 ng/mL) without evidence of structural recurrence. The secondary endpoint was the difference of QOL.
Conclusion
This study will evaluate whether surgery alone achieves similar BCR and improved QOL compared to RAI ablation in patients with low- to intermediate-risk PTC within 1 year.

Diagnosis and Treatment of Growth Hormone Deficiency: A Position Statement from Korean Endocrine Society and Korean Society of Pediatric Endocrinology: Jung Hee Kim, Hyun Wook Chae, Sang Ouk Chin, Cheol Ryong Ku, Kyeong Hye Park, Dong Jun Lim, Kwang Joon Kim, Jung Soo Lim, Gyuri Kim, Yun Mi Choi, Seong Hee Ahn, Min Ji Jeon, Yul Hwangbo, Ju Hee Lee, Bu Kyung Kim, Yong Jun Choi, Kyung Ae Lee, Seong-Su Moon, Hwa Young Ahn, Hoon Sung Choi, Sang Mo Hong, Dong Yeob Shin, Ji A Seo, Se Hwa Kim, Seungjoon Oh, Sung Hoon Yu, Byung Joon Kim, Choong Ho Shin, Sung-Woon Kim, Chong Hwa Kim, Eun Jig Lee; Endocrinol Metab. 2020;35(2):272-287. Published online June 24, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.2.272

6,692 View
297 Download
10 Citations

Abstract PDF PubReader ePub Crossref - TDM

Growth hormone (GH) deficiency is caused by congenital or acquired causes and occurs in childhood or adulthood. GH replacement therapy brings benefits to body composition, exercise capacity, skeletal health, cardiovascular outcomes, and quality of life. Before initiating GH replacement, GH deficiency should be confirmed through proper stimulation tests, and in cases with proven genetic causes or structural lesions, repeated GH stimulation testing is not necessary. The dosing regimen of GH replacement therapy should be individualized, with the goal of minimizing side effects and maximizing clinical improvements. The Korean Endocrine Society and the Korean Society of Pediatric Endocrinology have developed a position statement on the diagnosis and treatment of GH deficiency. This position statement is based on a systematic review of evidence and expert opinions.

Citations

Citations to this article as recorded by

Evaluation of Adult Height in Patients with Non-Permanent Idiopathic GH Deficiency
Agnese Murianni, Anna Lussu, Chiara Guzzetti, Anastasia Ibba, Letizia Casula, Mariacarolina Salerno, Marco Cappa, Sandro Loche
Endocrines.2023; 4(1): 169. CrossRef
Diagnosis of GH Deficiency Without GH Stimulation Tests
Anastasia Ibba, Sandro Loche
Frontiers in Endocrinology.2022;[Epub] CrossRef
Metabolic Impacts of Discontinuation and Resumption of Recombinant Human Growth Hormone Treatment during the Transition Period in Patients with Childhood-Onset Growth Hormone Deficiency
Yun Jeong Lee, Yunha Choi, Han-Wook Yoo, Young Ah Lee, Choong Ho Shin, Han Saem Choi, Ho-Seong Kim, Jae Hyun Kim, Jung Eun Moon, Cheol Woo Ko, Moon Bae Ahn, Byung-Kyu Suh, Jin-Ho Choi
Endocrinology and Metabolism.2022; 37(2): 359. CrossRef
A Radiomics-Based Model with the Potential to Differentiate Growth Hormone Deficiency and Idiopathic Short Stature on Sella MRI
Taeyoun Lee, Kyungchul Song, Beomseok Sohn, Jihwan Eom, Sung Soo Ahn, Ho-Seong Kim, Seung-Koo Lee
Yonsei Medical Journal.2022; 63(9): 856. CrossRef
Phenotypic spectrum of patients with mutations in CHD7: clinical implications of endocrinological findings
Ja Hye Kim, Yunha Choi, Soojin Hwang, Gu-Hwan Kim, Han-Wook Yoo, Jin-Ho Choi
Endocrine Connections.2022;[Epub] CrossRef
Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
Hyemi Kwon, Eun Roh, Chang Ho Ahn, Hee Kyung Kim, Cheol Ryong Ku, Kyong Yeun Jung, Ju Hee Lee, Eun Heui Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Jun Sung Moon, Jin Hwa Kim, Mi-kyung Kim
Endocrinology and Metabolism.2022; 37(6): 839. CrossRef
Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force
Eu Jeong Ku, Kyoung Jin Kim, Jung Hee Kim, Mi Kyung Kim, Chang Ho Ahn, Kyung Ae Lee, Seung Hun Lee, You-Bin Lee, Kyeong Hye Park, Yun Mi Choi, Namki Hong, A Ram Hong, Sang-Wook Kang, Byung Kwan Park, Moon-Woo Seong, Myungshin Kim, Kyeong Cheon Jung, Chan
Endocrinology and Metabolism.2021; 36(2): 322. CrossRef
Asian Conference on Tumor Ablation Guidelines for Adrenal Tumor Ablation
Byung Kwan Park, Masashi Fujimori, Shu-Huei Shen, Uei Pua
Endocrinology and Metabolism.2021; 36(3): 553. CrossRef
Asian Conference on Tumor Ablation guidelines for renal cell carcinoma
Byung Kwan Park, Shu-Huei Shen, Masashi Fujimori, Yi Wang
Investigative and Clinical Urology.2021; 62(4): 378. CrossRef
Diagnosis and Treatment of Adult Growth Hormone Deficiency
Jung Hee Kim
The Korean Journal of Medicine.2021; 96(5): 400. CrossRef

Corrigendum: Author's Name Correction. Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro): Jae Hoon Moon, Ji-hoon Kim, Eun Kyung Lee, Kyu Eun Lee, Sung Hye Kong, Yeo Koon Kim, Woo-Jin Jeong, Chang Yoon Lee, Roh-Eul Yoo, Yul Hwangbo, Young Shin Song, Min Joo Kim, Sun Wook Cho, Su-jin Kim, Eun-Jae Chung, June Young Choi, Chang Hwan Ryu, You Jin Lee, Jeong Hun Hah, Yuh-Seog Jung, Junsun Ryu, Yunji Hwang, Sue K. Park, Ho Kyung Sung, Ka Hee Yi, Do Joon Park, Young Joo Park; Endocrinol Metab. 2018;33(3):427-427. Published online August 14, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.3.427

2,762 View
38 Download
2 Citations

PDF PubReader ePub Crossref - TDM

Citations

Citations to this article as recorded by

Invasiveness and Metastatic Aggressiveness in Small Differentiated Thyroid Cancers: Demography of Small Papillary Thyroid Carcinomas in the Swedish Population
Haytham Bayadsi, Martin Bergman, Malin Sund, Joakim Hennings
World Journal of Surgery.2020; 44(2): 461. CrossRef
Clinical and pathologic predictors of lymph node metastasis in papillary thyroid microcarcinomas
Ling Zhao, Xiaoya Sun, Yukun Luo, Fulin Wang, Zhaohui Lyu
Annals of Diagnostic Pathology.2020; 49: 151647. CrossRef

Genome-Wide Association Studies of Autoimmune Thyroid Diseases, Thyroid Function, and Thyroid Cancer: Yul Hwangbo, Young Joo Park; Endocrinol Metab. 2018;33(2):175-184. Published online June 21, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.2.175

6,142 View
110 Download
45 Citations

Abstract PDF PubReader ePub Crossref - TDM

Thyroid diseases, including autoimmune thyroid diseases and thyroid cancer, are known to have high heritability. Family and twin studies have indicated that genetics plays a major role in the development of thyroid diseases. Thyroid function, represented by thyroid stimulating hormone (TSH) and free thyroxine (T4), is also known to be partly genetically determined. Before the era of genome-wide association studies (GWAS), the ability to identify genes responsible for susceptibility to thyroid disease was limited. Over the past decade, GWAS have been used to identify genes involved in many complex diseases, including various phenotypes of the thyroid gland. In GWAS of autoimmune thyroid diseases, many susceptibility loci associated with autoimmunity (human leukocyte antigen [HLA], protein tyrosine phosphatase, non-receptor type 22 [PTPN22], cytotoxic T-lymphocyte associated protein 4 [CTLA4], and interleukin 2 receptor subunit alpha [IL2RA]) or thyroid-specific genes (thyroid stimulating hormone receptor [TSHR] and forkhead box E1 [FOXE1]) have been identified. Regarding thyroid function, many susceptibility loci for levels of TSH and free T4 have been identified through genome-wide analyses. In GWAS of differentiated thyroid cancer, associations at FOXE1, MAP3K12 binding inhibitory protein 1 (MBIP)-NK2 homeobox 1 (NKX2-1), disrupted in renal carcinoma 3 (DIRC3), neuregulin 1 (NRG1), and pecanex-like 2 (PCNXL2) have been commonly identified in people of European and Korean ancestry, and many other susceptibility loci have been found in specific populations. Through GWAS of various thyroid-related phenotypes, many susceptibility loci have been found, providing insights into the pathogenesis of thyroid diseases and disease co-clustering within families and individuals.

Citations

Citations to this article as recorded by

Molecular Mechanisms in Autoimmune Thyroid Disease
Hernando Vargas-Uricoechea
Cells.2023; 12(6): 918. CrossRef
Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin
Poupak Fallahi, Silvia Martina Ferrari, Giusy Elia, Francesca Ragusa, Armando Patrizio, Sabrina Rosaria Paparo, Gianni Marone, Maria Rosaria Galdiero, Giovanni Guglielmi, Rudy Foddis, Alfonso Cristaudo, Alessandro Antonelli
Seminars in Cancer Biology.2022; 79: 203. CrossRef
The Relationship between PTPN22 R620W Polymorphisms and the Susceptibility to Autoimmune Thyroid Diseases: An Updated Meta-analysis
Huaiyong Wu, Siyuan Wan, Mengying Qu, Bingxuan Ren, Lixiang Liu, Hongmei Shen
Immunological Investigations.2022; 51(2): 438. CrossRef
Identification of Transcriptional Pattern Related to Immune Cell Infiltration With Gene Co-Expression Network in Papillary Thyroid Cancer
Meiye Li, Jimei Zhang, Zongjing Zhang, Ying Qian, Wei Qu, Zhaoshun Jiang, Baochang Zhao
Frontiers in Endocrinology.2022;[Epub] CrossRef
Analysis of rare genetic variation underlying cardiometabolic diseases and traits among 200,000 individuals in the UK Biobank
Sean J. Jurgens, Seung Hoan Choi, Valerie N. Morrill, Mark Chaffin, James P. Pirruccello, Jennifer L. Halford, Lu-Chen Weng, Victor Nauffal, Carolina Roselli, Amelia W. Hall, Matthew T. Oetjens, Braxton Lagerman, David P. vanMaanen, Goncalo Abecasis, Xiao
Nature Genetics.2022; 54(3): 240. CrossRef
Factors affecting recurrence in subacute granulomatous thyroiditis
Çiğdem Tura Bahadir, Merve Yilmaz, Elif Kiliçkan
Archives of Endocrinology and Metabolism.2022;[Epub] CrossRef
Shared etiology of type 1 diabetes and Hashimoto’s thyroiditis: a population-based twin study
Jakob Skov, Ralf Kuja-Halkola, Patrik K E Magnusson, Soffia Gudbjörnsdottir, Olle Kämpe, Sophie Bensing
European Journal of Endocrinology.2022; 186(6): 677. CrossRef
High Prevalence of Common Human Viruses in Thyroid Tissue
Therese Weider, Angelo Genoni, Francesco Broccolo, Trond H. Paulsen, Knut Dahl-Jørgensen, Antonio Toniolo, Sara Salehi Hammerstad
Frontiers in Endocrinology.2022;[Epub] CrossRef
B cells from anti-thyroid antibody positive, infertile women show hyper-reactivity to BCR stimulation
Timea Serény-Litvai, Anna Bajnok, Viktoria Temesfoi, Jasper Nörenberg, Greta Pham-Dobor, Ambrus Kaposi, Akos Varnagy, Kalman Kovacs, Sandor Pentek, Tamas Koszegi, Emese Mezosi, Timea Berki
Frontiers in Immunology.2022;[Epub] CrossRef
What do the structures of GCN5-containing complexes teach us about their function?
Dominique Helmlinger, Gábor Papai, Didier Devys, László Tora
Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms.2021; 1864(2): 194614. CrossRef
Genetic Susceptibility to Joint Occurrence of Polycystic Ovary Syndrome and Hashimoto’s Thyroiditis: How Far Is Our Understanding?
Natalia Zeber-Lubecka, Ewa E. Hennig
Frontiers in Immunology.2021;[Epub] CrossRef
Type 1 Diabetes and Autoimmune Thyroid Disease—The Genetic Link
Lara Frommer, George J. Kahaly
Frontiers in Endocrinology.2021;[Epub] CrossRef
Familial Risk of Hashimoto's Thyroiditis Among First-Degree Relatives: A Population-Based Study in Korea
Hyun Jung Kim, Sayada Zartasha Kazmi, Taeuk Kang, Seo Young Sohn, Dong-Sook Kim, Hoo Jae Hann, Hyeong Sik Ahn
Thyroid.2021; 31(7): 1096. CrossRef
Limited Genetic Overlap Between Overt Hashimoto’s Thyroiditis and Graves’ Disease in Twins: A Population-based Study
Jakob Skov, Jan Calissendorff, Daniel Eriksson, Patrik Magnusson, Olle Kämpe, Sophie Bensing, Ralf Kuja-Halkola
The Journal of Clinical Endocrinology & Metabolism.2021; 106(4): e1101. CrossRef
Endogenous and Synthetic Regulators of the Peripheral Components of the Hypothalamo-Hypophyseal-Gonadal and -Thyroid Axes
A. O. Shpakov
Neuroscience and Behavioral Physiology.2021; 51(3): 332. CrossRef
Programmed Cell Death-Ligand 1 (PD-L1) gene Single Nucleotide Polymorphism in Graves’ Disease and Hashimoto’s Thyroiditis in Korean Patients
Jee Hee Yoon, Min-ho Shin, Hee Nam Kim, Wonsuk Choi, Ji Yong Park, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
Endocrinology and Metabolism.2021; 36(3): 599. CrossRef
Predisposition to Graves’ disease and Graves’ ophthalmopathy by genetic variants of IL2RA
Juan Du, Xin Wang, Guiqin Tan, Wenwen Wei, Fangyu Zhou, Zhongzhi Liang, Hua Li, Hongsong Yu
Journal of Molecular Medicine.2021; 99(10): 1487. CrossRef
Association of IL-1β, NLRP3, and COX-2 Gene Polymorphisms with Autoimmune Thyroid Disease Risk and Clinical Features in the Iranian Population
Zahra Heidari, Saeedeh Salimi, Mohsen Rokni, Mahnaz Rezaei, Neshat Khalafi, Mahdieh Jafari Shahroudi, Azizallah Dehghan, Mohsen Saravani, Rafael S. De Molon
BioMed Research International.2021; 2021: 1. CrossRef
Genetic polymorphisms in the PCNXL2 gene are risk factors for thyroid cancer in the Chinese population
Runmei Hao, Peng Han, Ling Zhang, Ying Bi, Jinfeng Yan, Honghui Li, Yanxia Bai, Chongwen Xu, Baiya Li, Huajing Li
Future Oncology.2021; 17(34): 4677. CrossRef
Genetic Variants Associated with Thyroid Cancer Risk: Comprehensive Research Synopsis, Meta-Analysis, and Cumulative Epidemiological Evidence
Ran Ran, Gang Tu, Hui Li, Hao Wang, Exian Mou, Caiyang Liu, Yuan Seng Wu
Journal of Oncology.2021; 2021: 1. CrossRef
The Identification of Three Key Genes Related to Stemness in Thyroid Carcinoma through Comprehensive Analysis
Tonglong Zhang, Chunhong Yan, Zhengdu Ye, Xingling Yin, Tian-an Jiang
Combinatorial Chemistry & High Throughput Screening.2021; 24(3): 423. CrossRef
Thyroid autoimmune disorders and cancer
Silvia Martina Ferrari, Poupak Fallahi, Giusy Elia, Francesca Ragusa, Ilaria Ruffilli, Sabrina Rosaria Paparo, Alessandro Antonelli
Seminars in Cancer Biology.2020; 64: 135. CrossRef
Association of FCRL3 rs7528684 polymorphism with risk of Hashimoto's thyroiditis in Iranian patients
Kurosh Kalantar, Farzad Ghandehari, Saeed Malek-Hosseini, Hossein Golmoghaddam, Davood Rostamzadeh, Mohamad Hossein Dabbaghmanesh, Zahra Amirghofran
Meta Gene.2020; 24: 100663. CrossRef
Differentiated thyroid cancer and Hashimoto thyroiditis: Utility of the Afirma gene expression classifier
Vardan Papoian, Jennifer E. Rosen, Wen Lee, Leonard Wartofsky, Erin A. Felger
Journal of Surgical Oncology.2020; 121(7): 1053. CrossRef
Familial risks between Graves disease and Hashimoto thyroiditis and other autoimmune diseases in the population of Sweden
Hauke Thomsen, Xinjun Li, Kristina Sundquist, Jan Sundquist, Asta Försti, Kari Hemminki
Journal of Translational Autoimmunity.2020; 3: 100058. CrossRef
Association of rs944289, rs965513, and rs1443434 in TITF1/TITF2 with Risks of Papillary Thyroid Carcinoma and with Nodular Goiter in Northern Chinese Han Populations
Xin Zhang, Yulu Gu, Yong Li, Heran Cui, Xiaoli Liu, Hui Sun, Qiong Yu, Yaqin Yu, Yawen Liu, Siyan Zhan, Yi Cheng
International Journal of Endocrinology.2020; 2020: 1. CrossRef
FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid disease
Saedis Saevarsdottir, Thorunn A. Olafsdottir, Erna V. Ivarsdottir, Gisli H. Halldorsson, Kristbjorg Gunnarsdottir, Asgeir Sigurdsson, Ari Johannesson, Jon K. Sigurdsson, Thorhildur Juliusdottir, Sigrun H. Lund, Asgeir O. Arnthorsson, Edda L. Styrmisdottir
Nature.2020; 584(7822): 619. CrossRef
Genetic relationship between Hashimoto`s thyroiditis and papillary thyroid carcinoma with coexisting Hashimoto`s thyroiditis
Ohoud Subhi, Hans-Juergen Schulten, Nadia Bagatian, Roa'a Al-Dayini, Sajjad Karim, Sherin Bakhashab, Reem Alotibi, Alaa Al-Ahmadi, Manar Ata, Aisha Elaimi, Saad Al-Muhayawi, Majid Mansouri, Khalid Al-Ghamdi, Osman Abdel Hamour, Awatif Jamal, Jaudah Al-Mag
PLOS ONE.2020; 15(6): e0234566. CrossRef
Thyroid cancer and thyroid autoimmune disease: A review of molecular aspects and clinical outcomes
Natália Medeiros Dias Lopes, Hannah Hamada Mendonça Lens, André Armani, Poliana Camila Marinello, Alessandra Lourenço Cecchini
Pathology - Research and Practice.2020; 216(9): 153098. CrossRef
Immune gene signature delineates a subclass of thyroid cancer with unfavorable clinical outcomes
Jingtai Zhi, Jiaoyu Yi, Mengran Tian, Huijuan Wang, Ning Kang, Xiangqian Zheng, Ming Gao
Aging.2020; 12(7): 5733. CrossRef
VARIETY OF COMBINATIONS OF HASHIMOTO’S THYROIDITIS WITH OTHER BACKGROUND PATHOLOGY OF THYROID PARENCHEMA IN DIFFERENT FORMS OF THYROID CANCER
Yu. I. Karachentsev, V. M. Dubovik, I. V. Gopkalova, V. V. Khaziev, S. S. Sokolova, Y. P. Korchagin, N. G. Filonenko, M. Y. Sazonov, L. V. Gerasimenko
Bulletin of Problems Biology and Medicine.2020; 3(1): 105. CrossRef
Analysis of Polymorphisms rs7093069-IL-2RA, rs7138803-FAIM2, and rs1748033-PADI4 in the Group of Adolescents With Autoimmune Thyroid Diseases
Beata Sawicka, Hanna Borysewicz-Sańczyk, Natalia Wawrusiewicz-Kurylonek, Tommaso Aversa, Domenico Corica, Joanna Gościk, Adam Krętowski, Małgorzata Waśniewska, Artur Bossowski
Frontiers in Endocrinology.2020;[Epub] CrossRef
Familial associations for rheumatoid autoimmune diseases
Hauke Thomsen, Xinjun Li, Kristina Sundquist, Jan Sundquist, Asta Försti, Kari Hemminki
Rheumatology Advances in Practice.2020;[Epub] CrossRef
Familial risks between giant cell arteritis and Takayasu arteritis and other autoimmune diseases in the population of Sweden
Hauke Thomsen, Xinjun Li, Kristina Sundquist, Jan Sundquist, Asta Försti, Kari Hemminki
Scientific Reports.2020;[Epub] CrossRef
The Association of Obesity with Autoimmune Thyroiditis and Thyroid Function-Possible Mechanisms of Bilateral Interaction
Agnieszka Baranowska-Bik, Wojciech Bik, Henrik Falhammar
International Journal of Endocrinology.2020; 2020: 1. CrossRef
The Risk of Recurrence of Subacute Thyroiditis Is HLA-Dependent
Magdalena Stasiak, Bogusław Tymoniuk, Bartłomiej Stasiak, Andrzej Lewiński
International Journal of Molecular Sciences.2019; 20(5): 1089. CrossRef
FOXE1 inhibits cell proliferation, migration and invasion of papillary thyroid cancer by regulating PDGFA
Zheng Ding, Ronghu Ke, Yong Zhang, Youben Fan, Jianxia Fan
Molecular and Cellular Endocrinology.2019; 493: 110420. CrossRef
Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer
Kinga Hińcza, Artur Kowalik, Aldona Kowalska
Genes.2019; 10(7): 482. CrossRef
Thyroid Cancer: The Quest for Genetic Susceptibility Involving DNA Repair Genes
Santos, Gomes, Bastos, Gil, Azevedo, Ferreira, Limbert, Silva, Rueff
Genes.2019; 10(8): 586. CrossRef
Genetic Polymorphisms on 4q21.1 Contributed to the Risk of Hashimoto's Thyroiditis
Dachao Mo, Junjiu Li, Liang Peng, Zhiyuan Liu, Jieyun Wang, Jiru Yuan
Genetic Testing and Molecular Biomarkers.2019; 23(12): 837. CrossRef
A Weighted Genetic Risk Score Using Known Susceptibility Variants to Predict Graves Disease Risk
Yu-Ru Ma, Shuang-Xia Zhao, Lu Li, Feng Sun, Xiao-Ping Ye, Fei-Fei Yuan, Dan Jiang, Zheng Zhou, Qian-Yue Zhang, Yue-Yue Wan, Guang-Ya Zhang, Jing Wu, Rui-Jia Zhang, Ya Fang, Huai-Dong Song
The Journal of Clinical Endocrinology & Metabolism.2019; 104(6): 2121. CrossRef
Architects meets Repairers: The interplay between homeobox genes and DNA repair
Bruno César Feltes
DNA Repair.2019; 73: 34. CrossRef
Development of a prognostic index based on an immunogenomic landscape analysis of papillary thyroid cancer
Peng Lin, Yi-nan Guo, Lin Shi, Xiao-jiao Li, Hong Yang, Yun He, Qing Li, Yi-wu Dang, Kang-lai Wei, Gang Chen
Aging.2019; 11(2): 480. CrossRef
Selenium and Selenoproteins in Immune Mediated Thyroid Disorders
Liliana Santos, Celestino Neves, Miguel Melo, Paula Soares
Diagnostics.2018; 8(4): 70. CrossRef
Sex-specific genetic influence on thyroid-stimulating hormone and free thyroxine levels, and interactions between measurements: KNHANES 2013–2015
Young Ki Lee, Dong Yeob Shin, Hyejung Shin, Eun Jig Lee, Silvia Naitza
PLOS ONE.2018; 13(11): e0207446. CrossRef

Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro): Jae Hoon Moon, Ji-hoon Kim, Eun Kyung Lee, Kyu Eun Lee, Sung Hye Kong, Yeo Koon Kim, Woo-jin Jung, Chang Yoon Lee, Roh-Eul Yoo, Yul Hwangbo, Young Shin Song, Min Joo Kim, Sun Wook Cho, Su-jin Kim, Eun Jae Jung, June Young Choi, Chang Hwan Ryu, You Jin Lee, Jeong Hun Hah, Yuh-Seog Jung, Junsun Ryu, Yunji Hwang, Sue K. Park, Ho Kyung Sung, Ka Hee Yi, Do Joon Park, Young Joo Park; Endocrinol Metab. 2018;33(2):278-286. Published online June 21, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.2.278

3,958 View
68 Download
25 Citations

Abstract PDF PubReader ePub Crossref - TDM

Background

The ongoing Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro) aims to observe the natural course of papillary thyroid microcarcinoma (PTMC), develop a protocol for active surveillance (AS), and compare the long-term prognosis, quality of life, and medical costs between the AS and immediate surgery groups.

Methods

This multicenter prospective cohort study of PTMC started in June 2016. The inclusion criteria were suspicious of malignancy or malignancy based on fine needle aspiration or core needle biopsy, age of ≥18 years, and a maximum diameter of ≤1 cm. If there was no major organ involvement, no lymph node/distant metastasis, and no variants with poor prognosis, the patients were explained of the pros and cons of immediate surgery and AS before selecting AS or immediate surgery. Follow-up visits (physical examination, ultrasonography, thyroid function, and questionnaires) are scheduled every 6 months during the first 2 years, and then every 1 year thereafter. Progression was defined as a maximum diameter increase of ≥3, ≥2 mm in two dimensions, suspected organ involvement, or lymph node/distant metastasis.

Results

Among 439 enrolled patients, 290 patients (66.1%) chose AS and 149 patients (33.9%) chose immediate surgery. The median follow-up was 6.7 months (range, 0.2 to 11.9). The immediate surgery group had a larger maximum tumor diameter, compared to the AS group (7.1±1.9 mm vs. 6.6±2.0 mm, respectively; P=0.014).

Conclusion

The results will be useful for developing an appropriate PTMC treatment policy based on its natural course and risk factors for progression.

Citations

Citations to this article as recorded by

Psychological adjustment to initial treatment for low‐risk thyroid cancer: Preliminary study
Gabriella T. Seo, Mark L. Urken, Lauren E. Wein, Michael P. Saturno, Danielle Kapustin, Monica H. Xing, Lauren E. Yue, Eric M. Dowling, Tracey A. Revenson, Katherine J. Roberts, Robert Michael Tuttle
Head & Neck.2023; 45(2): 439. CrossRef
Active Surveillance of Thyroid Microcarcinomas: a Critical View
Claudio R. Cernea, Leandro Luongo Matos, Cecília Eugênio, Giovanna Mattos Ferreira, Yasmin Sa Cerqueira, Ana Kober N. Leite, Felipe A. B. Vanderlei, Dorival de Carlucci, Renato N. Gotoda, Flávio C. Hojaij, Vergilius J. F. Araújo-Filho
Current Oncology Reports.2022; 24(1): 69. CrossRef
Active Surveillance Versus Thyroid Surgery for Differentiated Thyroid Cancer: A Systematic Review
Roger Chou, Tracy Dana, Megan Haymart, Angela M. Leung, Ralph P. Tufano, Julie Ann Sosa, Matthew D. Ringel
Thyroid.2022; 32(4): 351. CrossRef
A Review of Active Surveillance of Papillary Thyroid Microcarcinoma
Cho Rok Lee
Journal of Endocrine Surgery.2022; 22(1): 1. CrossRef
Active Surveillance Versus Immediate Surgery for Low-Risk Papillary Thyroid Microcarcinoma Patients in South Korea: A Cost-Minimization Analysis from the MAeSTro Study
Kyungsik Kim, June Young Choi, Su-jin Kim, Eun Kyung Lee, Young Ki Lee, Jun Sun Ryu, Kyu Eun Lee, Jae Hoon Moon, Young Joo Park, Sun Wook Cho, Sue K. Park
Thyroid.2022; 32(6): 648. CrossRef
A cross-sectional survey of patient treatment choice in a multicenter prospective cohort study on active surveillance of papillary thyroid microcarcinoma (MAeSTro)
Yul Hwangbo, June Young Choi, Eun Kyung Lee, Chang Hwan Ryu, Sun Wook Cho, Eun Jae Chung, Jeong Hun Hah, Woo-Jin Jeong, Sue K. Park, Yuh-Seog Jung, Ji-hoon Kim, Min Joo Kim, Su-jin Kim, Yeo Koon Kim, Chang Yoon Lee, Ji Ye Lee, You Jin Lee, Hyeong Won Yu,
Thyroid.2022;[Epub] CrossRef
Progression of Low-Risk Papillary Thyroid Microcarcinoma During Active Surveillance: Interim Analysis of a Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma in Korea
Eun Kyung Lee, Jae Hoon Moon, Yul Hwangbo, Chang Hwan Ryu, Sun Wook Cho, June Young Choi, Eun-Jae Chung, Woo-Jin Jeong, Yuh-Seog Jung, Junsun Ryu, Su-jin Kim, Min Joo Kim, Yeo Koon Kim, Chang Yoon Lee, Ji Ye Lee, Hyeong Won Yu, Jeong Hun Hah, Kyu Eun Lee,
Thyroid.2022; 32(11): 1328. CrossRef
Indications and Strategy for Active Surveillance of Adult Low-Risk Papillary Thyroid Microcarcinoma: Consensus Statements from the Japan Association of Endocrine Surgery Task Force on Management for Papillary Thyroid Microcarcinoma
Iwao Sugitani, Yasuhiro Ito, Dai Takeuchi, Hirotaka Nakayama, Chie Masaki, Hisakazu Shindo, Masanori Teshima, Kazuhiko Horiguchi, Yusaku Yoshida, Toshiharu Kanai, Mitsuyoshi Hirokawa, Kiyomi Y. Hames, Isao Tabei, Akira Miyauchi
Thyroid.2021; 31(2): 183. CrossRef
Effect of Initial Treatment Choice on 2-year Quality of Life in Patients with Low-risk Papillary Thyroid Microcarcinoma
Jae Hoon Moon, Chang Hwan Ryu, Sun Wook Cho, June Young Choi, Eun-Jae Chung, Jeong Hun Hah, Yul Hwangbo, Woo-Jin Jeong, Yuh-Seog Jung, Ji-hoon Kim, Min Joo Kim, Su-jin Kim, Yeo Koon Kim, Chang Yoon Lee, Eun Kyung Lee, Ji Ye Lee, Kyu Eun Lee, You Jin Lee,
The Journal of Clinical Endocrinology & Metabolism.2021; 106(3): 724. CrossRef
Adoption of Active Surveillance for Very Low-Risk Differentiated Thyroid Cancer in the United States: A National Survey
Susan C Pitt, Nan Yang, Megan C Saucke, Nicholas Marka, Bret Hanlon, Kristin L Long, Alexandria D McDow, J P Brito, Benjamin R Roman
The Journal of Clinical Endocrinology & Metabolism.2021; 106(4): 1728. CrossRef
Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma
Min Ji Jeon, Yea Eun Kang, Jae Hoon Moon, Dong Jun Lim, Chang Yoon Lee, Yong Sang Lee, Sun Wook Kim, Min-Hee Kim, Bo Hyun Kim, Ho-Cheol Kang, Minho Shong, Sun Wook Cho, Won Bae Kim
Endocrinology and Metabolism.2021; 36(2): 359. CrossRef
Multifocality and Progression of Papillary Thyroid Microcarcinoma During Active Surveillance
Ryuta Nagaoka, Aya Ebina, Kazuhisa Toda, Tomoo Jikuzono, Marie Saitou, Masaomi Sen, Hiroko Kazusaka, Mami Matsui, Keiko Yamada, Hiroki Mitani, Iwao Sugitani
World Journal of Surgery.2021; 45(9): 2769. CrossRef
Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma
Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinology and Metabolism.2021; 36(4): 717. CrossRef
The Concept of Economic Evaluation and Its Application in Thyroid Cancer Research
Kyungsik Kim, Mijin Kim, Woojin Lim, Bo Hyun Kim, Sue K. Park
Endocrinology and Metabolism.2021; 36(4): 725. CrossRef
Genomic and Transcriptomic Characteristics According to Size of Papillary Thyroid Microcarcinoma
Young Shin Song, Byung-Hee Kang, Seungbok Lee, Seong-Keun Yoo, Young Sik Choi, Jungsun Park, Dong Yoon Park, Kyu Eun Lee, Jeong-Sun Seo, Young Joo Park
Cancers.2020; 12(5): 1345. CrossRef
Experience with Active Surveillance of Thyroid Low-Risk Carcinoma in a Developing Country
Alvaro Sanabria
Thyroid.2020; 30(7): 985. CrossRef
Association of Patient Age With Progression of Low-risk Papillary Thyroid Carcinoma Under Active Surveillance
Alexandra Koshkina, Rouhi Fazelzad, Iwao Sugitani, Akira Miyauchi, Lehana Thabane, David P. Goldstein, Sangeet Ghai, Anna M. Sawka
JAMA Otolaryngology–Head & Neck Surgery.2020; 146(6): 552. CrossRef
Active surveillance in low risk papillary thyroid carcinoma
Fabian Pitoia, Anabella Smulever
World Journal of Clinical Oncology.2020; 11(6): 320. CrossRef
Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival
Jolanta Krajewska, Aleksandra Kukulska, Malgorzata Oczko-Wojciechowska, Agnieszka Kotecka-Blicharz, Katarzyna Drosik-Rutowicz, Malgorzata Haras-Gil, Barbara Jarzab, Daria Handkiewicz-Junak
Frontiers in Endocrinology.2020;[Epub] CrossRef
The dilemma of papillary thyroid microcarcinoma management. To operate or not to operate, that is the question
Juan C Galofré
Endocrinología, Diabetes y Nutrición.2019; 66(8): 469. CrossRef
Computed Tomography for Detecting Cervical Lymph Node Metastasis in Patients Who Have Papillary Thyroid Microcarcinoma with Tumor Characteristics Appropriate for Active Surveillance
Dong-Hwa Lee, Yeo Koon Kim, Hyeong Won Yu, June Young Choi, So Yeon Park, Jae Hoon Moon
Thyroid.2019; 29(11): 1653. CrossRef
The dilemma of papillary thyroid microcarcinoma management. To operate or not to operate, that is the question
Juan C Galofré
Endocrinología, Diabetes y Nutrición (English ed.).2019; 66(8): 469. CrossRef
Longitudinal Assessment of Quality of Life According to Treatment Options in Low-Risk Papillary Thyroid Microcarcinoma Patients: Active Surveillance or Immediate Surgery (Interim Analysis of MAeSTro)
Sung Hye Kong, Junsun Ryu, Min Joo Kim, Sun Wook Cho, Young Shin Song, Ka Hee Yi, Do Joon Park, Yul Hwangbo, You Jin Lee, Kyu Eun Lee, Su-jin Kim, Woo-Jin Jeong, Eun-Jae Chung, Jeong Hun Hah, June Young Choi, Chang Hwan Ryu, Yuh-Seog Jung, Jae Hoon Moon,
Thyroid.2019; 29(8): 1089. CrossRef
Ultrasound-guided percutaneous laser ablation for papillary thyroid microcarcinoma: a retrospective analysis of 37 patients
Lili Ji, Qin Wu, Jun Gu, Xuedong Deng, Wei Zhou, Xing Fan, Feng Zhou
Cancer Imaging.2019;[Epub] CrossRef
Evolving management considerations in active surveillance for micropapillary thyroid carcinoma
Allen S. Ho, Irene Chen, Michelle Melany, Wendy L. Sacks
Current Opinion in Endocrinology & Diabetes and Obesity.2018; 25(5): 353. CrossRef

Acute Hyperglycemia Associated with Anti-Cancer Medication: Yul Hwangbo, Eun Kyung Lee; Endocrinol Metab. 2017;32(1):23-29. Published online March 20, 2017; DOI: https://doi.org/10.3803/EnM.2017.32.1.23

4,727 View
94 Download
33 Citations

Abstract PDF PubReader Crossref - TDM

Hyperglycemia during chemotherapy occurs in approximately 10% to 30% of patients. Glucocorticoids and L-asparaginase are well known to cause acute hyperglycemia during chemotherapy. Long-term hyperglycemia is also frequently observed, especially in patients with hematologic malignancies treated with L-asparaginase-based regimens and total body irradiation. Glucocorticoid-induced hyperglycemia often develops because of increased insulin resistance, diminished insulin secretion, and exaggerated hepatic glucose output. Screening strategies for this condition include random glucose testing, hemoglobin A1c testing, oral glucose loading, and fasting plasma glucose screens. The management of hyperglycemia starts with insulin or sulfonylurea, depending on the type, dose, and delivery of the glucocorticoid formulation. Mammalian target of rapamycin (mTOR) inhibitors are associated with a high incidence of hyperglycemia, ranging from 13% to 50%. Immunotherapy, such as anti-programmed death 1 (PD-1) antibody treatment, induces hyperglycemia with a prevalence of 0.1%. The proposed mechanism of immunotherapy-induced hyperglycemia is an autoimmune process (insulitis). Withdrawal of the PD-1 inhibitor is the primary treatment for severe hyperglycemia. The efficacy of glucocorticoid therapy is not fully established and the decision to resume PD-1 inhibitor therapy depends on the severity of the hyperglycemia. Diabetic patients should achieve optimized glycemic control before initiating treatment, and glucose levels should be monitored periodically in patients initiating mTOR inhibitor or PD-1 inhibitor therapy. With regard to hyperglycemia caused by anti-cancer therapy, frequent monitoring and proper management are important for promoting the efficacy of anti-cancer therapy and improving patients' quality of life.

Citations

Citations to this article as recorded by

Increased risk of incident diabetes after therapy with immune checkpoint inhibitor compared with conventional chemotherapy: A longitudinal trajectory analysis using a tertiary care hospital database
Minyoung Lee, Kyeongseob Jeong, Yu Rang Park, Yumie Rhee
Metabolism.2023; 138: 155311. CrossRef
Analysis of the Incidence of Type 2 Diabetes, Requirement of Insulin Treatment, and Diabetes-Related Complications among Patients with Cancer
Su Jung Lee, Chulho Kim, Hyunjae Yu, Dong-Kyu Kim
Cancers.2023; 15(4): 1094. CrossRef
A Case of Pembrolizumab-Induced Diabetic Ketoacidosis and Hyperthyroidism in a Patient With Recurrent Esophageal Adenocarcinoma
Jonathan Salangsang, Surendra Sapkota, Sanjeev Kharel, Prakash Gupta, Abhishek Kalla
Cureus.2023;[Epub] CrossRef
Link between Blood Cell-Associated Inflammatory Indices and Chemotherapy-Induced Hyperglycemia in Women Affected with Breast Cancer: Clinical Studies
Krishna Prasad, Suresh Rao, Sanath Kumar Hegde, Thomas George, Rhea Katherine D'souza, Sucharitha Suresh, Manjeshwar Shrinath Baliga
South Asian Journal of Cancer.2023;[Epub] CrossRef
Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia
Marcus D. Goncalves, Azeez Farooki
Integrative Cancer Therapies.2022; 21: 153473542110731. CrossRef
Metformin Induced Cognitive Impairment and Neuroinflammation in CMF-Treated Rats
Ahmad H. Alhowai, Yasser Almogbel, Ahmed A.H. Abdel, Maha A. Aldubay, Hani A. Alfheeaid, Shatha G. Felemban, Sridevi Chigurupat, Ibrahim F. Alharbi, Hindi S. Alharbi
International Journal of Pharmacology.2022; 18(2): 228. CrossRef
Glucose Influences the Response of Glioblastoma Cells to Temozolomide and Dexamethasone
Anna M Bielecka-Wajdman, Tomasz Ludyga, Daria Smyk, Wojciech Smyk, Magdalena Mularska, Patrycja Świderek, Wojciech Majewski, Christina Susanne Mullins, Michael Linnebacher, Ewa Obuchowicz
Cancer Control.2022; 29: 107327482210754. CrossRef
Cardiometabolic Comorbidities in Cancer Survivors
Leah L. Zullig, Anthony D. Sung, Michel G. Khouri, Shelley Jazowski, Nishant P. Shah, Andrea Sitlinger, Dan V. Blalock, Colette Whitney, Robin Kikuchi, Hayden B. Bosworth, Matthew J. Crowley, Karen M. Goldstein, Igor Klem, Kevin C. Oeffinger, Susan Dent
JACC: CardioOncology.2022; 4(2): 149. CrossRef
Assessment of metabolic syndrome parameters in pediatric acute lymphoblastic leukemia survivors
Omer Kartal, Orhan Gürsel
Indian Journal of Cancer.2022;[Epub] CrossRef
Glucose deprivation reduces proliferation and motility, and enhances the anti-proliferative effects of paclitaxel and doxorubicin in breast cell lines in vitro
Maitham A. Khajah, Sarah Khushaish, Yunus A. Luqmani, Yi-Hsien Hsieh
PLOS ONE.2022; 17(8): e0272449. CrossRef
Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression
Kyeong-Min Lee, Yeo Jin Hwang, Gwon-Soo Jung
Biochemical and Biophysical Research Communications.2022; 626: 135. CrossRef
Glucocorticoid-Induced Hyperglycemia in Oncologic Outpatients: A Narrative Review Using the Quadruple Aim Framework
Ihab Kandil, Erin Keely
Canadian Journal of Diabetes.2022; 46(7): 730. CrossRef
Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors
Atika AlHarbi, Majed Alshamrani, Mansoor Khan, Abdelmajid Alnatsheh, Mohammed Aseeri
Medical Sciences.2022; 10(4): 65. CrossRef
The Assessment of the Hypothalamic-Pituitary-Adrenal Axis After Oncological Treatment in Pediatric Patients with Acute Lymphoblastic Leukemia
Barbara Hull, Anna Wedrychowicz, Magdalena Ossowska, Aleksandra Furtak, Joanna Badacz, Szymon Skoczeń, Jerzy B. Starzyk
Journal of Clinical Research in Pediatric Endocrinology.2022; 14(4): 393. CrossRef
Targeting Mitochondria and Oxidative Stress in Cancer- and Chemotherapy-Induced Muscle Wasting
Joshua R. Huot, Dryden Baumfalk, Aridai Resendiz, Andrea Bonetto, Ashley J. Smuder, Fabio Penna
Antioxidants & Redox Signaling.2022;[Epub] CrossRef
Economic burden of diabetes among medicare beneficiaries with cancer
Cassidi C McDaniel, F Ellen Loh, Devan M Rockwell, Courtney P McDonald, Chiahung Chou
Journal of Pharmaceutical Health Services Research.2021; 12(2): 142. CrossRef
The prognostic outcome of ‘type 2 diabetes mellitus and breast cancer’ association pivots on hypoxia-hyperglycemia axis
Ilhaam Ayaz Durrani, Attya Bhatti, Peter John
Cancer Cell International.2021;[Epub] CrossRef
Increased risk of diabetes in cancer survivors: a pooled analysis of 13 population-based cohort studies
Y. Xiao, H. Wang, Y. Tang, J. Yan, L. Cao, Z. Chen, Z. Shao, Z. Mei, Z. Jiang
ESMO Open.2021; 6(4): 100218. CrossRef
Sublethal concentrations of high glucose prolong mitotic arrest in a spindle assembly checkpoint activity dependent manner in budding yeast
Pinar B. Thomas, Elif E. Cavusoglu, Nur Kaluc
Biologia.2021; 76(12): 3883. CrossRef
Hyperglycemia in Childhood Acute Lymphoblastic Leukemia During Induction Chemotherapy
Nengcy Erlina Tasik Rerung, Andi Cahyadi, Nur Rochmah, Maria Christina Shanty Larasati, Mia Ratwita Andarsini, Muhammad Faizi, IDG Ugrasena, Bambang Permono
MEDICINUS.2021; 34(1): 18. CrossRef
Effect of Acute Chemotherapy on Glucose Levels in Rats
Ahmad H. Alhowail, Gena S. Alfawzan, Maha A. Aldubayan, Lolwah S. Alsalam
International Journal of Pharmacology.2020; 16(3): 276. CrossRef
Predictors of Disease Progression or Performance Status Decline in Patients Undergoing Neoadjuvant Therapy for Localized Pancreatic Head Adenocarcinoma
Alessandro Paniccia, Ana L. Gleisner, Mazen S. Zenati, Amr I. Al Abbas, Jae Pil Jung, Nathan Bahary, Kenneth K. W. Lee, David Bartlett, Melissa E. Hogg, Herbert J. Zeh, Amer H. Zureikat
Annals of Surgical Oncology.2020; 27(8): 2961. CrossRef
Fasting to enhance Cancer treatment in models: the next steps
Jing Zhang, Yanlin Deng, Bee Luan Khoo
Journal of Biomedical Science.2020;[Epub] CrossRef
Concurrent diabetic ketoacidosis and pancreatitis in Paediatric acute lymphoblastic leukemia receiving L-asparaginase
Patel Zeeshan Jameel, Sham Lohiya, Amol Dongre, Sachin Damke, Bhavana B. Lakhkar
BMC Pediatrics.2020;[Epub] CrossRef
Hyperglycemia during Adjuvant Chemotherapy as a Prognostic Factor in Breast Cancer Patients without Diabetes
Ha Rim Ahn, Sang Yull Kang, Hyun Jo Youn, Sung Hoo Jung
Journal of Breast Cancer.2020; 23(4): 398. CrossRef
Side effects of adjuvant chemotherapy and their impact on outcome in elderly breast cancer patients: a cohort study
Valentina Zanuso, Vittorio Fregoni, Lorenzo Gervaso
Future Science OA.2020; : FSO617. CrossRef
Incidence of Hyperglycemia/Secondary Diabetes in Women who have Undergone Curative Chemotherapy for Breast Cancer: First Study from India
Suresh Rao, Krishna Prasad, Soniya Abraham, Thomas George, Supreeth Kakkaje Chandran, Manjeshwar Shrinath Baliga
South Asian Journal of Cancer.2020; 09(03): 130. CrossRef
Hyperglycemic ADR Distribution of Doxorubicin From VigiBase
Jincheng Yang, Jun Yang
American Journal of Therapeutics.2019; 26(3): e428. CrossRef
Hyperglycemia During Childhood Cancer Therapy: Incidence, Implications, and Impact on Outcomes
Allison Grimes, Ashraf Mohamed, Jenna Sopfe, Rachel Hill, Jane Lynch
JNCI Monographs.2019; 2019(54): 132. CrossRef
Steroid-induced diabetes in cancer patients
Gemma Dinn
Journal of Prescribing Practice.2019; 1(12): 610. CrossRef
Risk Factors for Doxorubicin-Induced Serious Hyperglycaemia-Related Adverse Drug Reactions
Jincheng Yang, Yu Wang, Kang Liu, Wen Yang, Jianying Zhang
Diabetes Therapy.2019; 10(5): 1949. CrossRef
Effect of glucose and palmitate environment on proliferation and migration of PC3‐prostate cancer cells
Lívia Prometti Rezende, Maria Raquel Unterkircher Galheigo, Breno Costa Landim, Amanda Rodrigues Cruz, Françoise Vasconcelos Botelho, Renata Graciele Zanon, Rejane Maira Góes, Daniele Lisboa Ribeiro
Cell Biology International.2019; 43(4): 373. CrossRef
Incidence of Diabetes After Cancer Development
Yul Hwangbo, Danbee Kang, Minwoong Kang, Saemina Kim, Eun Kyung Lee, Young Ae Kim, Yoon Jung Chang, Kui Son Choi, So-Youn Jung, Sang Myung Woo, Jin Seok Ahn, Sung Hoon Sim, Yun Soo Hong, Roberto Pastor-Barriuso, Eliseo Guallar, Eun Sook Lee, Sun-Young Kon
JAMA Oncology.2018; 4(8): 1099. CrossRef

Characterization of Incidentally Detected Adrenal Pheochromocytoma.: Ye An Kim, Yul Hwangbo, Min Joo Kim, Hyung Jin Choi, Je Hyun Seo, Yenna Lee, Soo Heun Kwak, Eu Jeong Ku, Tae Jung Oh, Eun Roh, Jae Hyun Bae, Jung Hee Kim, Kyoung Soo Park, Seong Yeon Kim; Endocrinol Metab. 2012;27(2):132-137. Published online June 20, 2012; DOI: https://doi.org/10.3803/EnM.2012.27.2.132

1,738 View
23 Download
3 Citations

Abstract PDF

BACKGROUND
In approach to an adrenal incidentaloma, early exclusion of pheochromocytoma is clinically important, due to the risk of catecholamine crisis. The aims of this study are to investigate the characteristics of incidentally detected pheochromocytomas, compared with that of the other adrenal incidentalomas, and to compare these characteristics with those of symptomatic pheochromocytomas. METHODS: In this retrospective study, we reviewed the medical records of 198 patients with adrenal incidentaloma from 2001 to 2010. We analyzed the clinical, laboratory and radiological data of pheochromocytomas, in comparison with those of the other adrenal incidentalomas. We also compared the characteristics of these incidentally detected pheochromocytomas with the medical records of 28 pathologically proven pheochromocytomas, diagnosed based on typical symptoms. RESULTS: Among the 198 patients with adrenal incidentaloma, nineteen patients were diagnosed with pheochromocytoma. Pheochromocytomas showed larger size and higher Hounsfield unit at precontrast computed tomography (CT) than did non-pheochromocytomas. All pheochromocytomas were larger than 2.0 cm, and the Hounsfield units were 19 or higher in precontrast CT. When both criteria of size > 2.0 cm and Hounsfield unit > 19 were met, the sensitivity and specificity for the diagnosis of pheochromocytoma were 100% and 79.3%, respectively. Compared with patients with pheochromocytoma, diagnosed based on typical symptoms, patients with incidentally detected pheochromocytoma were older, presented less often with hypertension, and showed lower levels of 24-hour urine metanephrine. CONCLUSION: Adrenal incidentaloma with < 2.0 cm in size or < or = 19 Hounsfield units in precontrast CT imaging was less likely to be a pheochromocytoma. Patients with incidentally discovered pheochromocytoma showed lower catecholamine metabolites, compared with those patients with symptomatic pheochromocytoma.

Citations

Citations to this article as recorded by

Guidelines for the Management of Adrenal Incidentaloma: the Korean Endocrine Society, Committee of Clinical Practice Guidelines
Jung-Min Lee, Mee Kyoung Kim, Seung-Hyun Ko, Jung-Min Koh, Bo-Yeon Kim, Sang-Wan Kim, Soo-Kyung Kim, Hae-Jin Kim, Ohk-Hyun Ryu, Juri Park, Jung-Soo Lim, Seong Yeon Kim, Young Kee Shong, Soon Jib Yoo
The Korean Journal of Medicine.2017; 92(1): 4. CrossRef
Clinical Guidelines for the Management of Adrenal Incidentaloma
Jung-Min Lee, Mee Kyoung Kim, Seung-Hyun Ko, Jung-Min Koh, Bo-Yeon Kim, Sang Wan Kim, Soo-Kyung Kim, Hae Jin Kim, Ohk-Hyun Ryu, Juri Park, Jung Soo Lim, Seong Yeon Kim, Young Kee Shong, Soon Jib Yoo
Endocrinology and Metabolism.2017; 32(2): 200. CrossRef
Characterization of Incidentally Detected Adrenal Pheochromocytoma
Soon Jib Yoo, Woohyeon Kim
Endocrinology and Metabolism.2012; 27(2): 116. CrossRef

Author index